Skip to content

An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)

An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030472
Enrollment
Unknown
Registered
2020-03-03
Start date
2020-02-25
Completion date
Unknown
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Ganovo/ ritonavir oral+conventional treatment
Control group:Conventional treatment

Sponsors

Shenyang Sixth People's Hospita
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years old; 2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection; 3. patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days); 4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration; 5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration; 6. Patients who voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR 30 times / min; or SaO2 / SpO2 =C, AST > 5 times upper limit); 4. Patients with contraindications specified in the instructions of ritonavir tablets; 5. The patient who previous or ongoing use of protease inhibitors; 6. The pregnancy test of female subjects in the screening period was positive; 7. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).?

Design outcomes

Primary

MeasureTime frame
Rate of composite advers outcomes: SPO2, PaO2/FiO2 and respiratory rate;

Secondary

MeasureTime frame
Clinical remission rate and time;novel coronavirus nucleic acid detection;

Countries

China

Contacts

Public ContactYe Gu

Shenyang Sixth People's Hospital

sylykjk@163.com+86 18502468189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026